Revaccination of Children after Completion of Standard Chemotherapy for Acute Leukemia
|
|
- Margaret Wheeler
- 5 years ago
- Views:
Transcription
1 MAJOR ARTICLE Revccintion of Children fter Completion of Stndrd Chemotherpy for Acute Leukemi Soonie R. Ptel, 1 Miguel Ortín, 1 Bernrd J. Cohen, 2 Ry Borrow, 5 Dine Irving, 3 Jonne Sheldon, 3 nd Pul T. Heth 4 1 Peditric Oncology Deprtment, Royl Mrsden Hospitl, Sutton, 2 Virus Reference Deprtment, Center for Infections, Helth Protection Agency, 3 Protein Reference Unit, St. Georges Hospitl, nd 4 Vccine Institute nd Child Helth, St. George s University of London, London, nd 5 Meningococcl Reference Unit, Mnchester Medicl Microbiology Prtnership, Mnchester Royl Infirmry, Mnchester, United Kingdom (See the rticle by Ptel et l. on pges nd the editoril commentry by Chisholm on pges 643 5) Bckground. After the tretment of ptients with cute leukemi, there is decrese in vccine-specific ntibody nd n incresed susceptibility to certin vccine-preventble diseses. A simple revccintion schedule is wrrnted. Method. Fifty-nine children (ge, 1 18 yers) who hd completed stndrd chemotherpy in ccordnce with Medicl Reserch Council of United Kingdom protocols were recruited. All children received single dose of Hemophilus influenze type b (Hib), tetnus, diphtheri, cellulr pertussis, meningococcus C, polio, mesles, mumps, nd rubell vccines 6 months fter completion of tretment. Antibody concentrtions were mesured before vccintion nd 2 4 weeks nd 12 months fter vccintion. Results. Prevccintion ntibody levels were protective for ll ptients for tetnus (geometric men concentrtion [GMC], 0.13 IU/mL; 95% CI, IU/mL), for 87% for Hib (GMC, 0.5 mg/ml; 95% CI, mg/ml), for 71% for mesles (GMC, 301 miu/ml; 95% CI, miu/ml), for 12% for meningococcus C (geometric men titer [GMT], 1:2.9; 95% CI, 1:2.2 to 1:3.9), nd for 11% for ll 3 poliovirus serotypes. Revccintion resulted in significnt increse in levels of ntibody to ech vccine ntigen, with 100% of ptients chieving optiml ntitetnus ntibody concentrtions (defined s 10.1 IU/mL; 1.5 IU/mL; 95% CI, IU/ ml), 93% chieving optiml ntibody concentrtions to Hib (defined s 11.0 mg/ml; 6.5mg/mL; 95% CI, mg/ml), 94% chieving optiml ntibody concentrtions to mesles (defined s 120 miu/ml; 2720 miu/ml; 95% CI, miu/ml), 96% chieving optiml ntibody concentrtions to meningococcus C (defined s 1:8; 1:1000; 95% CI, 1:483 1:2064), nd 85% chieving optiml ntibody concentrtions to ll the 3 poliovirus serotypes (defined s 1:8). For the mjority of subjects, protection persisted for t lest 12 months fter vccintion. Conclusion. Revccintion of children fter stndrd chemotherpy is importnt, nd protection cn be chieved in the mjority of these children using simple schedule of 1 vccine dose t 6 months fter completion of leukemi therpy. Leukemi is the most common form of childhood mlignncy; cute lymphoblstic leukemi (ALL) represents 80% of cses, nd cute myeloid leukemi (AML) represents 15% of cses [1]. The tretment of British children hs followed consecutive Medicl Reserch Council of United Kingdom protocols for ALL (MRC-UKALL), nd the tretment of chil- Received 27 July 2006; ccepted 18 October 2006; electroniclly published 24 Jnury Reprints or correspondence: Dr. Soonie R. Ptel, Peditric Dept., Mydy University Hospitl, Croydon, CR7 7YE, UK (soonier@doctors.org.uk). Clinicl Infectious Diseses 2007; 44: by the Infectious Diseses Society of Americ. All rights reserved /2007/ $15.00 DOI: / dren hs followed Medicl Reserch Council of United Kingdom protocols for AML (MRC- UKAML) protocols. Both protocols provide risk-strtified therpy [2, 3]. Over the yers, tretment hs gretly improved the durtion of disese-free survivl [2, 3]. It hs been suggested tht leukemi itself hs n effect on the dptive immune system [4, 5] nd, therefore, my impir ntibody responses to vccine ntigens. ALL nd AML trget lymphoid nd myeloid progenitor cells, respectively; their tretments lso trget these cells. Thus, both the disese nd its tretment will inevitbly cuse immunosuppression. Chemotherpy to tret cute leukemi is immunosuppressive. B lymphocyte [6] nd T lymphocyte levels decrese [7], nd there is reduction of totl Ig levels Revccintion of Children CID 2007:44 (1 Mrch) 635
2 t the completion of chemotherpy. IgM, IgG [5, 8 10], nd IgG2 re specificlly ffected [11]. B lymphocyte function nd T lymphocyte function usully recover 6 months fter completion of chemotherpy, lthough recovery my tke up to 1 yer [6, 7]. Normliztion of Ig levels usully occurs fter 1 yer [9]. An incresing number of children now survive s result of improvements in leukemi tretment nd supportive cre. Therefore, it is importnt to study the long-term effects of stndrd chemotherpy, such s its effects on immunity to vccine-preventble diseses. Reltively few studies hve exmined this specificlly in ptients treted for leukemi. Such studies hve generlly demonstrted decrese in protective ntibody levels fter completion of tretment [12 19]. Some hve suggested tht this decrese my be similr to tht experienced by helthy individuls [20]. Studies evluting revccintion ginst mesles, mumps, rubell, poliovirus, tetnus, diphtheri, nd Hemophilus influenze type b (Hib) fter completion of chemotherpy hve reveled vrible immune responses [12, 14 17, 19, 21]. To our knowledge, there re no published studies evluting the immunogenicity of meningococcus C conjugte (MCC) vccines in ptients treted for cute leukemi. There re few guidelines for the revccintion of children treted with stndrd ntileukemi chemotherpy. US guidelines recommend commencement of revccintion 3 months fter completion of chemotherpy [22]. The current UK guidelines recommend single dose of diphtheri-tetnus cellulr pertussis (DTP), inctivted poliovirus (IPV), MCC, Hib conjugte, nd mesles-mumps-rubell (MMR) vccines t 6 months fter completion of stndrd chemotherpy [23]. These recommendtions were primrily bsed on expert opinion nd dt from limited number of published studies [23]. The objectives of this study were to evlute these guidelines nd to specificlly evlute (1) the persistence of vccine-specific ntibody nd (2) the immunogenicity of 1 dose of MMR, tetnus toxoid, IPV, Hib conjugte, nd MCC vccines given to children t lest 6 months fter completion of stndrd chemotherpy for leukemi. PATIENTS AND METHODS Ptient popultion. The study ws conducted over 2-yer period (1 October 2002 through 30 September 2004). were recruited from the peditric deprtment t the Royl Mrsden Hospitl (Sutton, United Kingdom). Eligible ptients were previously vccinted children (ge, 1 18 yers) who hd completed stndrd chemotherpy 6 months before recruitment in ccordnce with the MRC- UKALL protocols (UKALL-97, UKALL-99, nd, for ptients with disese relpse, UKALL-R2) for those nd the MRC-UKAML protocols (UKAML10 or UKAML12) for those [2, 3]. The tretment regimen supported by the MRC-UKALL protocols is risk-strtified into regimens A, B, nd C, in which regimen A is the lest intensive nd regimen C is the most intensive. Informed consent ws obtined from the ptient or his/her prent. who refused to receive 1 specific vccine were still included in the study. Children were only excluded if there ws recognized contrindiction to receipt of vccine. Clinicl dt on ech ptient were obtined from the ptient, prents, nd ptient records. Dt on pst vccintions were obtined from prents or the ptient s generl prctitioner. Vccines nd schedule. When possible, the vccintions were given in the 2 sets. DTP (Infnrix, GlxoSmithKline), IPV (Imovx, AventisPsteur), nd Hib conjugte (Hiberix, GlxoSmithKline) vccines were dministered initilly, nd MCC (Meningitec, Wyeth) nd MMR (MMR II, Aventis- Psteur) vccines were dministered 1 month lter. When possible, blood smples were obtined for serologic testing t the sme time s they were obtined for routine blood tests. Blood smples were collected on the dy tht the revccintions were commenced, 2 4 weeks fter receipt of ech set of vccintions, nd 1 yer fter the commencement of revccintions. Five to 10 ml of blood ws collected. Blood ws centrifuged, nd serum ws seprted nd frozen in liquots t 20 C on the sme dy t The Royl Mrsden Hospitl, until the smples were tested in btches. Serum smples were trnsported frozen to the vrious lbortories. Antibody ssys. Serum ntibody concentrtions or titers were mesured for the following ntigens: Hib; tetnus; poliovirus serotypes 1, 2, nd 3; mesles; nd Neisseri meningitidis group C. Tetnus nd Hib ssys were performed t the Protein Reference Unit of St. George s Hospitl (London, United Kingdom). ELISA methods were used to mesure IgG ntibodies to tetnus toxoid (with n in-house method vlidted by the Protein Reference Unit) nd polyribosylribitol phosphte (PRP; Bindzyme; the Binding Site). A neutrliztion ssy ws used to detect neutrlizing ntibodies ginst poliovirus serotypes 1, 2, nd 3 nd ws performed t the Helth Protection Agency (Colindle, London) [24]. The plque reduction neutrliztion ssy ws used to mesure the level of neutrlizing mesles ntibodies. Titers were reported s the reciprocl of the highest serum dilution required to reduce the plques of the chllenge virus by 50%. End point titers were converted into concentrtions by direct comprison with the World Helth Orgniztion stndrd for ntimesles serum [25]; this ssy ws performed t the Helth Protection Agency. The level of serum bctericidl ntibody (SBA) ginst meningococcus C ws determined by serum bctericidl ssy using bby rbbit serum s n exogenous complement source [26]. SBA titers re expressed s the reciprocl of the finl serum dilution yielding 50% killing of 636 CID 2007:44 (1 Mrch) Ptel et l.
3 Tble 1. Chrcteristics of children with cute lymphoblstic leukemi (ALL) or cute myeloid leukemi (AML). For ll ptients All children (n p 59) Children (n p 46) Children (n p 13) Sex, no. of ptients Mle 34 Femle 25 Age t dignosis, medin yers (rnge) 5.4 ( ) 5.25 ( ) 6.7 ( ) Age t vccintion, medin yers (rnge) 8.0 ( ) 8.1 (4.1 18) 7.5 ( ) Time from end of tretment to vccintion, medin yers (IQR) 0.58 ( ) 0.58 ( ) 0.8 ( ) Time from vccintion nd serologic testing, medin dys (IQR) 31 ( ) Tretment regimen received, no. of ptients MRC-UKALL-A MRC-UKALL-B MRC-UKALL-C MRC-UKALLR MRC-UKAML NOTE. IQR, interqurtile rnge; MRC-UKALL, Medicl Reserch Council of United Kingdom protocols for tretment of ALL; MRC-UKAML, Medicl Reserch Council of United Kingdom protocols for tretment of AML. bcteri. This ssy ws performed t the Meningococcl Reference Unit (Mnchester, United Kingdom). Sttisticl nlysis. For sttisticl nlysis, ntibody concentrtions or titers tht were less thn the limit of the ssy s sensitivity were ssigned vlues equl to one-hlf of the lower detection limit. All ntibody concentrtions or titers were logtrnsformed to clculte geometric men concentrtion (GMC) or geometric men (GMT), with 95% CIs. Dt did not conform to norml distribution, so comprisons of GMC or GMT before nd fter vccintion (pired smples) were performed using the Wilcoxon signed rnk test, comprisons between 2 groups (unpired smples) were performed using the Mnn-Whitney U test, nd 3-wy comprisons were performed using the Kruskl-Wllis test. Comprisons of proportions were nlyzed by Fisher s exct test. Correltion between 2 continuous vribles ws nlyzed by Spermn s correltion coefficient. Dt re lso reported in terms of proportions of ptients who experienced seroconversion (defined s 4-fold increse in ntibody concentrtion or titer) nd who ttined protective concentrtions or titers. For Hib, nti-prp ntibody concentrtions 0.15 nd 1.0 mg/ml re thought to correlte with short-term nd long-term protection, respectively [27]. For tetnus, ntitetnus ntibody concentrtions of 0.01 nd 0.1 IU/ ml re correlted with short-term nd long-term protection, respectively [28]. Any detectble titer of neutrlizing ntibody ginst poliovirus is considered to be protective; for this study, neutrlizing ntibody titers 1:8 re considered to correlte with protection [28]. For mesles, concentrtion 120 miu/ ml is believed to correlte with protection (Cohen B, Audet S, Andrews N, Beeler J, on behlf of The World Helth Orgniztion Working Group on Mesles Plque Reduction Neutrliztion Test; personl communiction). For meningococcus C, n SBA titer 1:8 before vccintion nd n SBA titer 1: 128 fter vccintion re believed to correlte with protection [29, 30]. SBA titers in the rnge 1:8 1:64 fter vccintion re considered to be protective if vccintion results in 4-fold increse in the SBA titer [29]. Anlysis findings were considered to be sttisticlly significnt t 2-tiled P vlue of.05. Dt were nlyzed using SPSS sttisticl softwre, version 12.0 for Windows (SPSS). The ethics committee of the Royl Mrsden Hospitl pproved the study. RESULTS A totl of 59 ptients were recruited in the study. Demogrphic informtion regrding the ptients is presented in tble 1. The number of blood smples obtined vried by vccine ntigen nd time point, nd findings re shown in tbles 2 6. Fewer smples were vilble t the lter time points becuse ptients declined to provide dditionl smples, ptients did not ttend visit for blood smple collection, disese relpsed (2 ptients), or the time point ws not reched during the study period. Differing numbers of vccine ntigens were the result of insufficient serum smple sizes to llow ll ssys to be performed For ech vccine, there ws significnt increse in the ntibody concentrtion or titer fter dministrtion of 1 dose of Revccintion of Children CID 2007:44 (1 Mrch) 637
4 Tble 2. Geometric men concentrtion (GMC) of serum polyribosylribitol phosphte ntibody, before nd fter receipt of 1 dose of Hemophilus influenze type b conjugte vccine. Period No. of ptients with dt GMC of serum polyribosylribitol phosphte ntibody, mg/ml (95% CI) Before vccintion (n p 52) ( ) 0.5 ( ) 0.45 ( ) b After vccintion (n p 43) ( ) c 7.5 ( ) d 2.6 ( ) d One yer fter vccintion (n p 15) ( ) NOTE. Pired pre- nd postvccintion serologic test results were vilble for 40 ptients. ALL, cute lymphoblstic leukemi; AML, cute myeloid leukemi. P!.001 for before versus fter vccintion. b P p.02 for before versus fter vccintion. c P p.02 for fter versus 1 yer fter vccintion. d P!.05 for ptients versus ptients. Tble 3. Period Geometric men concentrtion of serum ntitetnus ntibody, before nd fter receipt of 1 dose of tetnus toxoid vccine. No. of ptients with dt the vccine. No correltion between prevccintion or postvccintion responses to ny vccine ws found for the following fctors: time between completion of tretment nd vccintion, time between vccintion nd serologic testing, ptient ge t dignosis nd t vccintion, pst vccintion history, nd MRC-UKALL tretment regimen. There were no significnt differences between ptients nd those with regrd to prevccintion ntibody levels. hd significntly greter increse in ntibody concentrtion in response to vccintion with Hib conjugte, tetnus toxoid, nd IPV vccines thn did ptients. The type of leukemi, however, did not significntly influence the proportion of ptients with protective responses ginst ny vccine ntigen. Hib. Ninety-five percent of ptients hd received t lest 1 dose of Hib conjugte vccine before the dignosis of leukemi. Before vccintion with Hib conjugte vccine, 86.5% of ptients hd nti-prp concentrtions 0.15 mg/ml, nd 25% hd concentrtions 1.0 mg/ml. There ws significnt increse in ntibody concentrtion fter vccintion (tble 2). Overll, 75% of ptients hd 4-fold increse in concentrtion, with 100% chieving concentrtion 0.15 mg/ml nd 93% chieving concentrtion 1.0 mg/ml. Twelve months fter vccintion, ntibody concentrtions hd significntly decresed (tble 2), lthough the concentrtion remined 1.0 mg/ml for ll ptients. Tetnus. hd received 3 doses of tetnus toxoid vccine before the dignosis of leukemi. Before vccintion, ll ptients hd n ntitetnus ntibody concentrtion 0.01 IU/mL, nd 57% hd concentrtion 0.1 IU/mL. There ws significnt increse in ntibody concentrtion fter vccintion (tble 3). Overll, 90% of ptients hd 4-fold increse in ntibody concentrtion, nd ll chieved concentrtion 0.1 IU/mL. Twelve months fter vccintion, ntibody concentrtions hd significntly decresed (tble 3), lthough the concentrtion remined 0.1 IU/mL for ll ptients. Poliovirus. hd received t lest 3 doses of polio vccine prior to the dignosis of leukemi. Before vccintion, only 11% of ptients hd protective levels of ntibody titer to ll 3 poliovirus serotypes. Protective titers to serotypes 1, 2, nd 3 were present in 67%, 60%, nd 14.5% of ptients, respectively. There ws significnt difference in the prevccintion ntibody GMT between serotypes; the GMT of serotype 3 ws significntly lower thn tht of serotypes 1 nd 2 (tble 4). After vccintion, there ws significnt increse in ntibody titers (tble 4). Overll, 85% of ptients chieved pro- GMC of serum ntitetnus ntibody, IU/mL (95% CI) Before vccintion (n p 54) ( ) 0.1 ( ) 0.26 ( ) After vccintion (n p 41) ( ) b 1.9 ( ) c 0.33 ( ) c One yer fter vccintion (n p 16) ( ) NOTE. Pired pre- nd postvccintion serologic test results were vilble for 39 ptients. ALL, cute lymphoblstic leukemi; AML, cute myeloid leukemi. P!.001 b P!.01 c P!.01 for before versus fter vccintion. for fter versus 1 yer fter vccintion. for ptients versus ptients. 638 CID 2007:44 (1 Mrch) Ptel et l.
5 Tble 4. vccine. Geometric men titer (GMT) of polio-neutrlizing ntibody, before nd fter receipt of 1 dose of inctivted poliovirus Period, poliovirus serotype No. of ptients with dt GMT of polio-neutrlizing ntibody (95% CI) Before vccintion (n p 55) Serotype ( ),b 9.8 ( ) 13.7 ( ) Serotype ( ),b 7.7 (6 9.9) 11.9 ( ) Serotype ( ),b 4.6 (4 5.2) 5.9 ( ) c After vccintion (n p 39) 31 8 Serotype 1 39 ( ) d 46.8 (30 79) e 16 ( ) e Serotype (24 59) 50 (30 83) e 12.3 (7.3 21) e Serotype 3 31 ( ) 41 (24 69) e 10.4 ( ) e One yer fter vccintion (n p 19) 15 4 Serotype ( ) Serotype 2 19 ( ) Serotype 3 12 (7 20.7) NOTE. Pired pre- nd postvccintion serologic test results were vilble for 36 ptients. ALL, cute lymphoblstic leukemi; AML, cute myeloid leukemi. P!.001 for before versus fter vccintion. b P!.001 for serotype 3 versus serotypes 1 nd 2. c P!.05 for before versus fter vccintion. d P!.05 for fter versus 1 yer fter vccintion. e P!.05 for ptients versus ptients. tective levels of ntibody titer to ll 3 serotypes; 95% chieved protective levels for serotype 1, 87% chieved protective levels for serotype 2, nd 87% chieved protective levels for serotype 3. More ptients chieved 4-fold increse in ntibody titers to serotype 3 (64%) thn to the other serotypes (50% for serotype 1 nd 58% for serotype 2). After vccintion, there were no significnt differences in ntibody GMTs between the serotypes. Twelve months fter vccintion, there ws decrese in the GMT for ll serotypes, nd the decrese ws sttisticlly significnt for serotype 1 (tble 4); only 47% of ptients still hd protective levels of ntibody titer to ll 3 serotypes t this time point. Mesles. Ninety-two percent of ptients hd received 1 dose of MMR vccine before the dignosis of leukemi. Before vccintion, 73.5% of ptients (75% of ptients with prior Tble 5. Geometric men concentrtion (GMC) of mesles-neutrlizing ntibody, before nd fter receipt of 1 dose of mesles-mumpsrubell vccine. Period No. of ptients with dt MMR vccintion nd 25% of ptients without prior MMR vccintion) hd ntibody concentrtions 120 miu/ml. There ws significnt increse in ntibody concentrtion fter dministrtion of single dose of MMR vccine (tble 5); 94% of ptients chieved protective concentrtions, nd 43% hd 4-fold increse in the concentrtion. Twelve months fter vccintion, there ws decrese in ntibody concentrtions, lthough the levels remined protective for ll ptients. Meningococcus C. Only 40% of ptients hd received dose of MCC vccine before the dignosis of leukemi. Before vccintion, 12% of children hd SBA titers 1:8. Of the children who hd received MCC before the commencement of chemotherpy, 17% hd protective titers. There ws significnt increse in the SBA titer fter vccintion (tble 6) tht ws independent of prior MCC vccintion sttus. Ninety-six GMC of mesles-neutrlizing ntibody, miu/ml (95% CI) Before vccintion (n p 49) ( ) 221 ( ) 700 ( ) After vccintion (n p 36) ( ) 3053 ( ) 1527 ( ) One yer fter vccintion (n p 17) ( ) NOTE. Pired pre- nd postvccintion serologic test results were vilble for 28 ptients. ALL, cute lymphoblstic leukemi; AML, cute myeloid leukemi. P!.001 for before versus fter vccintion. Revccintion of Children CID 2007:44 (1 Mrch) 639
6 Tble 6. Geometric men titer (GMT) of meningococcus C serum bctericidl ntibody, before nd fter receipt of 1 dose of meningococcus C conjugte vccine. Period No. of ptients with dt GMT of meningococcus C serum bctericidl ntibody (95% CI) Before vccintion (n p 49) ( ) 2.3 ( ) 2.5 ( ) b After vccintion (n p 28) ( ) 1120 ( ) 588 ( ) NOTE. Pired pre- nd postvccintion serologic test results were vilble for 26 ptients. ALL, cute lymphoblstic leukemi; AML, cute myeloid leukemi. P.001 for before versus fter vccintion. b P.05 for before versus fter vccintion. percent of children chieved titers 1:128 nd hd 4-fold increse in titer. There ws insufficient serum vilble to evlute the persistence of titers t 12 months fter vccintion. DISCUSSION At medin time of 7 months fter completion of stndrd chemotherpy for ALL nd AML, the mjority of children in our study hd levels of ntibody greter thn the minimum protective thresholds for tetnus (100%), Hib (87%), nd mesles (71%) ntigens. However, only 11% hd protective titers to ll poliovirus serotypes, despite receipt of previous vccintion with polio vccines, nd only 12% hd protective titers ginst N. meningitidis group C. These quoted protective levels my be relevnt only to previously helthy individuls nd my not be long lsting. Therefore, it is desirble to chieve higher levels in children recently completing tretment for leukemi, nd revccintion progrm is logicl. In keeping with other published studies [16, 17, 19], our ptients chieved good immune response to the vccine ntigens studied, with the mjority of children chieving protective ntibody responses. Some studies hve demonstrted tht younger ptient ge t vccintion is ssocited with more rpid decrese in protective ntibody levels [8, 9, 15, 17]. This ws not evident in our cohort. The intensity of ALL tretment cn influence immune responses [13, 16, 18]; most of our ptients received ALL tretment in ccordnce with the lest intensive MRC-UKALL regimen, nd 17% received tretment in ccordnce with the most intensive regimen; tretment intensity did not pper to influence immunity to the vccine ntigens studied. There were reltively few children who received the most intensive regimen ( n p 8), so this conclusion must be viewed with cution. Becuse ALL is disorder of lymphoid cells, it would seem logicl tht ALL nd its tretment my hve greter influence on dptive immune functions thn AML. Surprisingly, in our cohort, the ntibody response to ll vccines ws lower in ptients thn in those significntly so for Hib, tetnus, nd poliovirus vccines. Despite this, good levels of protection were chieved fter dministrtion of 1 dose of vccine. It should be noted tht there were only 13 ptients, nd this low number my limit our conclusions. It is not cler why ptients my hve poorer response, nd this group merits dditionl study, becuse they my benefit from second dose of vccine. There re few studies compring the influence of ALL nd AML on vccintion responses; one showed tht ptients hve lower levels of tetnus ntibody thn do ptients t the time of completion of chemotherpy [31]. The incidence of Hib disese is higher in children with leukemi thn in helthy children [32]. The nti-prp ntibody GMC of our ptients is similr to recently published previling nti-prp GMC in helthy, 2 4-yer-old British children [33]. Vccintion of our ptients resulted in significnt increse in the ntibody GMC to 6.5 mg/ml. One yer fter vccintion, the nti-prp GMC of our ptients hd decresed to 3.2 mg/ ml, but the level remined protective in ll children. Decresing ntibody concentrtions over time hve been demonstrted in children with mlignncies but re clerly feture in helthy children lso [32, 34]. All of the children in our study hd mintined protection to tetnus, nd ll chieved good responses to dose of tetnus toxoid vccine. Other studies hve reported lower rtes of mintennce of protective tetnus immunity (rnge, 38% 85% of ptients) [16 19]. As with our results, revccintion with single dose of tetnus toxoid vccine in other studies lso resulted in protective concentrtions in 77% 100% of ptients [16 18]. There re no dt vilble regrding immunity to meningococcl C disese nd immune response to MCC vccine fter leukemi chemotherpy. MCC vccine ws licensed in the United Kingdom in 1999, nd until recently, there hs been reltively little use in other countries. Therefore, this is, to our knowledge, the first study to evlute immune responses to MCC vccintion in this popultion. The previling SBA GMT in helthy infnts before vccintion is similr to tht in our cohort before vccintion [35]. 640 CID 2007:44 (1 Mrch) Ptel et l.
7 One dose of MCC vccine ppered to be sufficient for study children. However, we hve no dt on the persistence of titers 11 yer fter vccintion. Wning immunity in the United Kingdom hs resulted in the recent introduction of booster dose for young children. Additionl study of children with leukemi is wrrnted to ssess the durtion of protection ginst meningococcus C infection nd the need for lter booster doses. Mesles cn cuse life-thretening infection in immunocompromised children [36]. Limited dt re vilble regrding the incidence nd severity of mesles in children treted for leukemi. Our ptients, like those in previous studies [15, 17, 20], demonstrted lower rtes of seroconversion fter mesles vccintion thn did helthy individuls [37]. Some of our ptients did not hve ny response to mesles vccintion; however, the mjority chieved protective concentrtions fter receipt of 1 dose. One yer fter vccintion, levels remined protective in ll ptients. The seroconversion rtes of our ptients to IPV vccine re similr to those reported in helthy individuls [38]. As with other groups [39, 40], we observed tht levels of ntibody titer ginst serotype 3 were lower thn the levels of titer ginst serotypes 1 nd 2, both before nd fter vccintion. Becuse vccintion resulted in more ptients chieving 4-fold increse in ntibody to serotype 3, this difference ws no longer significnt fter vccintion. In this study, we did not formlly evlute the cost of universl revccintion fter leukemi tretment, compred with the cost of testing nd then selective revccintion. However, protective concentrtions or titers in this popultion my not be s vlid s in helthy children, leving open the question regrding wht levels to use s the bsis for revccintion. Furthermore, there re some vccines for which no serologicl correlte of protection exists (e.g., pertussis) or for which, in routine prctice, it is too difficult to hve levels mesured (e.g., polio). Clerly, for mny subjects, selective policy will lso men undergoing blood test nd then receiving n injection (s opposed to just receiving n injection). Universl revccintion is likely to be the esiest pproch from logisticl viewpoint. We hve demonstrted tht children who re treted in ccordnce with MRC-UKALL nd MRC-UKAML protocols mintin reltively good level of immunity ginst some vccine ntigens nd chieve protective ntibody responses to Hib, tetnus, meningococcus C, mesles, nd poliovirus with revccintion with 1 dose of vccine given 6 months fter completion of leukemi tretment. Therefore, we recommend this simple revccintion schedule. Additionl studies to evlute the response to vccintions given erlier fter completion of leukemi tretment should now be considered. Acknowledgments We thnk ll the children nd prents who prticipted in this study, s well s Yvonne Wright, who helped vccinte the children. Finncil support. The Children s Fund, Royl Mrsden Hospitl. Potentil conflicts of interest. St. George s Hospitl University of London nd P.T.H. hve received recent reserch grnts from Wyeth nd Snofi Psteur. R.B. hs received recent reserch grnts from Wyeth nd Bxter Bioscience nd hs been n d hoc consultnt to GlxoSmithKline, Snofi Psteur, Bxter Bioscience, nd Fujisw. All honorri re pid to Mnchester Children s University Hospitl Trust. All other uthors: no conflicts. References 1. Crist WM, Pui C-H. The leukemis. In: Behrmn RE, Kliegmn RM, Arvin AM, eds. Nelson textbook of peditrics, 15th ed. Pennsylvni: Prism Sunders, 1996: Chessels JM, Richrds SM, Biley CC, Lilleymn JS, Eden T. Gender nd tretment outcome in childhood lymphoblstic leukemi: report from the MRC UKALL trils. Br J Hemtol 1995; 89: Whetley K, Burnett AK, Goldstone AH, et l. A simple, robust, vlidted nd highly predictive index for the determintion of risk-directed therpy in cute myeloid leukemi derived from the MRC AML 10 tril. United Kingdom Reserch Council s Adult nd Childhood Leukemi Working Prties. Br J Hemtol 1999; 107: Spickermnn D, Guse A, Pfreundschuh M, Von Klle AK, Bohlen Diehl V. Impired ntibody levels to tetnus toxoid nd pneumococcl polyscchrides in cute leukemis. Leuk Lymphom 1994; 16: Abrhmsson J, Mrky I, Mellnder L. Immunoglobulin levels nd lymphocyte response to mitogenic stimultion in children with mlignnt disese during tretment nd follow-up. Act Peditr 1995; 84: Alnko S, Pelliniemi TT, Slmi TT. Recovery of blood B-lymphocytes nd serum immunoglobulins fter chemotherpy for childhood cute lymphoblstic leukemi. Cncer 1992; 69: Alnko S, Slmi TT, Pelliniemi TT. Recovery of blood T-cell subsets fter chemotherpy for childhood cute lymphoblstic leukemi. Peditr Hemtol Oncol 1994; 11: Cver TE, Slobod KS, Flynn PM, et l. Profound bnormlity of the B/T lymphocyte rtio during chemotherpy for peditric cute lymphoblstic leukemi. Leukemi 1998; 12: Mustf MM, Buchnn GR, Winick NJ, et l. Immune recovery in children with mlignncy fter cesstion of chemotherpy. J Peditr Hemtol Oncol 1998; 20: Mrtin Ibnez I, Arce Css A, Cruz Mrtinez O, Estell Agudo J, Mrtin Mteos MA. Humorl immunity in peditric ptients with cute lymphoblstic leukemi. Allergol Immunolpthol 2003; 31: Kristinsson VH, Kristinsson JR, Jonmundsson GK, Jonsson OG, Thorsson AV, Hrldsson A. Immunoglobulin clss nd subclss concentrtions fter tretment of childhood leukemi. Peditr Hemtol Oncol 2001; 18: Vn der Does-vn den Berg A, Hermns J, Ngel J, vn Steenis G. Immunity to diptheri, pertussis, tetnus nd poliomyelitis in children with cute lymphoblstic leukemi fter cesstion of chemotherpy. Peditrics 1981; 67: Ridgwy D, Wolff LJ, Deforest A. Immuniztion response vries with intensity of cute lymphoblstic leukemi therpy. Am J Dis Child 1991; 145: Smith S, Schiffmn G, Krylcin G, Bongur V. Immunodeficiency in long-term survivors of cute lymphoblstic leukemi treted with Berlin-Frnkfurt-Munster therpy. J Peditr 1995; 127: Nilsson A, De Milito A, Engström P, et l. Current chemotherpy protocols for childhood cute lymphoblstic leukemi induce loss of humorl immunity to virl vccintion ntigens. Peditrics 2002; 109: Ek T, Mellnder L, Hhn-Zoric M, Abrhmsson J. Intensive tretment Revccintion of Children CID 2007:44 (1 Mrch) 641
8 for childhood cute lymphoblstic leukemi reduces immune responses to diphtheri, tetnus nd Hemophilus influenze type b. J Peditr Hemtol Oncol 2004; 26: Zignol M, Percchi M, Tridello G, et l. Assessment of humorl immunity to poliomyelitis, tetnus, heptitis B, mesles, rubell, nd mumps in children fter chemotherpy. Cncer 2004; 101: Fioredd F, Plebni A, Hnu G, et l. Re-immunistion schedule in leukemic children fter intensive chemotherpy: possible strtegy. Eur J Hemtol 2005; 74: Vn Tilburg CM, Snders EAM, Rovers MM, Wolfs TFW, Bierings MB. Loss of ntibodies nd response to (re-)vccintion in children fter tretment for cute lymphoblstic leukemi: systemtic review. Leukemi 2006; 20: Ercn TE, Soycn LY, Apk H, et l. Antibody titers nd immune response to diphtheri-tetnus-pertussis nd mesles-mumps-rubell vccintion in children treted for cute lymphoblstic leukemi. J Peditr Hemtol Oncol 2005; 27: Kung FH, Orgel HA, Wllce WW, Hmburger RN. Antibody production following immunistion with diphtheri nd tetnus toxoids in children receiving chemotherpy during remission of mlignnt disese. Peditrics 1984; 74: Centers for Disese Control nd Prevention. Recommendtions of the Advisory Committee on Immuniztion Prctices (ACIP): use of vccines nd immune globulins in persons with ltered immunocompetence. MMWR Recomm Rep 1993; 42(RR-4): Royl College of Peditrics nd Child Helth (RCPCH). Immuniztion of the immunocompromised child: best prctice sttement. RCPCH, Albrecht P, vn Steenis G, vn Wezel AL, Slk JE. Stndrdiztion of poliovirus neutrlizing ntibody tests. Rev Infect Dis 1984; 6(Suppl 2): S Mrkowitz LE, Sepulved J, Diz-Orteg JL, et l. Immunistion of six-month-old infnts with different doses of Edmonston-Zgreb nd Schwrz mesles vccines. N Engl J Med 1990; 322: Mslnk SE, Gheesling LL, LiButti DE, et l. Stndrdiztion nd multi-lbortory comprison of Neisseri Meningitidis serogroup A nd C serum bctericidl ssys. Clin Dign Lb Immunol 1997; 4: Käythy H, Peltol H, Krnko V, Mäkelä P. The protective level of serum ntibodies to the cpsulr polyscchride of Hemophilus influenze type b. J Infect Dis 1983; 147: Plotkin SA. Immunologic correltes of protection induced by vccintion. Peditr Infect Dis J 2001; 20: Borrow R, Andrews N, Goldbltt D, Miller E. Serologicl bsis for the use of meningococcl sergroup C conjugte vccines in the United Kingdom: re-evlution of correltes of protection. Infect Immun 2001; 69: Andrews N, Borrow R, Miller E. Vlidtion of serologicl correlte of protection for meningococcl C conjugte vccine using efficcy estimtes from post-licensure surveillnce in Englnd. Clin Dign Lb Immunol 2003; 10: Hmmrström V, Puksen K, Svensson H, Oberg G, Pul C, Ljungmn P. Tetnus immunity in ptients with hemtologicl mlignncy. Support Cre Cncer 1998; 6: Feldmn S, Gigliotti F, Shenep JL, Roberson PK, Lott L. Risk of Hemophilus influenze type b disese in children with cncer nd response of immunocompromised leukemic children to conjugte vccine. J Infect Dis 1990; 161: Johnson N, Ruggeberg JU, Blfour GF, et l. Hemophilus influenze type b reemergence fter combintion immuniztion. Emerg Infect Dis 2004; 12: Heth PT, Booy R, Azzoprdi HJ, et l. Antibody concentrtion nd clinicl protection fter Hib conjugte vccintion in the United Kingdom. JAMA 2000; 284: Richmond P, Borrow R, Miller E, et l. Meningococcl serogroup C conjugte vccine is immunogenic in infncy nd primes for memory. J Infect Dis 1999; 179: Kpln LJ, Dum RS, Smron M, McCrthy CA. Severe mesles in immunocompromised ptients. JAMA 1992; 267: Robertson CM, Bennett VJ, Jefferson N, Myon-White RT. Serologicl evlution of mesles, mumps, nd rubell vccine. Arch Dis Child 1988; 63: Sutter RW, Ptrirc PA, Suleimn AJ, et l. Prlytic poliomyelitis in Omn: ssocition between regionl differences in ttck rte nd vritions in ntibody responses to orl poliovirus vccine. Int J Epidemiol 1993; 22: Ljungmn P, Durj V, Mgnius L. Response to immunistion ginst polio fter llogeneic mrrow trnsplnttion. Bone Mrrow Trnsplnt 1991; 7: Moriniere BJ, vn Loon FP, Rhodes PH, et l. Immunogenecity of supplementl dose of orl versus inctivted poliovirus vccine. Lncet 1993; 341: CID 2007:44 (1 Mrch) Ptel et l.
PNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationInvasive Pneumococcal Disease Quarterly Report. July September 2017
Invsive Pneumococcl Disese Qurterly Report July September 2017 Prepred s prt of Ministry of Helth contrct for scientific services by Rebekh Roos Helen Heffernn October 2017 Acknowledgements This report
More informationCheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More informationClinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Powell County. Public Health and Safety Division
Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Yellowstone County. Public Health and Safety Division
Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Lewis & Clark County. Public Health and Safety Division
Community Helth Profile 2015 Lewis & Clrk County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Missoula County. Public Health and Safety Division
Community Helth Profile 2015 Missoul County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Anaconda- Deer Lodge County. Public Health and Safety Division
Community Helth Profile 2015 Ancond- Deer Lodge County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12
More informationCommunity. Profile Carter County. Public Health and Safety Division
Community Helth Profile 2015 Crter County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationImmunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly
Brzilin Journl of Medicl nd Biologicl Reserch (2005) 38: 251-260 Immunogenicity of pneumococcl vccine ISSN 0100-879X 251 Immunogenicity of 23-vlent pneumococcl polyscchride vccine in Brzilin elderly V.
More informationA review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital
MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground
More informationSeasonal influenza vaccination programme country profile: Ireland
Sesonl influenz vccintion progrmme country profile: Irelnd 2012 13 Seson Bckground informtion Influenz immunistion policy nd generl fcts bout Irelnd Volume indices of GDP per cpit in 2011 nd 2013 (EU-
More informationInvasive Pneumococcal Disease Quarterly Report July September 2018
Invsive Pneumococcl Disese Qurterly Report July Septemer Introduction Since 17 Octoer 2008, invsive pneumococcl disese (IPD) hs een notifile to the locl Medicl Officer of Helth under the Helth Act 1956.
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationHepatitis A virus (HAV) infection contributes approximately
Multiple Fctors Contribute to Positive Results for Heptitis A Virus Immunoglobulin M Antibody Adnn Altoom, MD, PhD; M. Qsim Ansri, MD; Jennifer Cuthbert, MD Context. In the United Sttes, successful vccintion
More informationof 333 children who had been successfully immunized close contact with measles patients. 1 million), Zhejiang Province, a closed area in
Durtion of immunity following immuniztion with live mesles vccine: 15 yers of observtion in Zhejing Province, Chin Di Bin,1 Chen Zhihui,2 Liu Qichng,3 Wu Ting,4 Guo Chengyin,4 Wng Xingzi,5 Fng Hnhu,1 &
More informationEfficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationSupplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More informationComparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight
Bone Mrrow Trnsplnttion, (1999) 23, 867 873 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Comprison of utologous peripherl blood stem cell dosing by idel
More informationFeeding state and age dependent changes in melaninconcentrating hormone expression in the hypothalamus of broiler chickens
Supplementry Mterils Epub: No 2017_23 Vol. 65, 2018 https://doi.org/10.183/bp.2017_23 Regulr pper Feeding stte nd ge dependent chnges in melninconcentrting hormone expression in the hypothlmus of broiler
More informationAssessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II
Assessment of Depression in Multiple Sclerosis Vlidity of Including Somtic Items on the Beck Depression Inventory II Peggy Crwford, PhD; Noh J. Webster, MA Signs nd symptoms of multiple sclerosis (MS)
More informationImpact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors
Originl Article Impct of Positive Nodl Metstses in Ptients with Thymic Crcinom nd Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, nd Jennifer L. Sullivn, MD Introduction: Thymic crcinoms
More informationComparison of three simple methods for the
J. clin. Pth. (1967), 2, 5 Comprison of three simple methods for the ssessment of 'free' thyroid hormone T. M. D. GIMLETTE1 From the Rdio-Isotope Lbortory, St. Thoms's Hospitl, London SYNOPSIS A dilysis
More informationXII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV
XII. HIV/AIDS Knowledge bout HIV Trnsmission nd Misconceptions bout HIV One of the most importnt prerequisites for reducing the rte of HIV infection is ccurte knowledge of how HIV is trnsmitted nd strtegies
More informationThe RUTHERFORD-2 trial in heterozygous FH: Results and implications
The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of
More informationARTICLE ABSTRACT. PEDIATRICS Volume 119, Number 6, June peds doi: /peds.
ARTICLE Comprison of the Sfety nd Immunogenicity of Refrigertor-Stble Versus Frozen Formultion of ProQud (Mesles, Mumps, Rubell, nd Vricell Virus Vccine Live) Henry H. Bernstein, DO, Kren Eves, BS b, Kristy
More informationDevelopment and Persistence of Local and Systemic Antibody
JOURNAL OF CLINICAL MICROBIOLOGY, Jn. 1986, p. 66-72 0095-1137/86/010066-07$02.00/0 Copyright C) 1986, Americn Society for Microbiology Vol. 23, No. 1 Development nd Persistence of Locl nd Systemic Antibody
More informationEFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE
Swine Dy 21 EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE J. M. DeRouchey, M. D. Tokch, J. L. Nelssen, R. D. Goodbnd, S. S. Dritz 1, J. C. Woodworth, M. J. Webster, B. W.
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationEVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1
Swine Dy 2001 Contents EVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1 C. W. Hstd, S. S. Dritz 2, J. L. Nelssen, M. D. Tokch, nd R. D. Goodbnd Summry Two trils were
More informationFat intake in patients newly diagnosed with type 2 diabetes: a 4-year follow-up study in general practice
Originl ppers Ft intke in ptients newly dignosed with type 2 dibetes: 4-yer follow-up study in generl prctice Floris A vn de Lr, Eloy H vn de Lisdonk, Peter L B J Lucssen, J M H Tigchelr, Sski Meyboom,
More informationEvaluation of Tests for Rabies Antibody and Analysis of
JOURNAL OF CLINICAL MICROBIOLOGY, Mr. 1977, p. 263-267 Copyright C 1977 Americn Society for Microbiology Vol. 5, No. 3 Printed in U.S.A. Evlution of Tests for Rbies Antibody nd Anlysis of Serum Responses
More informationCorrelations Between Cytogenetic and Molecular Monitoring Among Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Originl Articles Correltions Between Cytogenetic nd Moleculr Monitoring Among Ptients With Newly Dignosed Chronic Myeloid Leukemi in Chronic Phse Post Hoc Anlyses of the Rtionle nd Insight for Gleevec
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More informationOpioid Use and Survival at the End of Life: A Survey of a Hospice Population
532 Journl of Pin nd Symptom Mngement Vol. 32 No. 6 December 2006 NHPCO Originl Article Opioid Use nd Survivl t the End of Life: A Survey of Hospice Popultion Russell K. Portenoy, MD, Un Sibircev, BA,
More informationViral hepatitis in Bucharest
Virl heptitis in Buchrest C. Pquet,1 V.T. Bbes,2 J. Drucker,3 B. Senemud,4 & A. Dobrescu5 A seroprevlence survey of virl heptitis ws conducted in Buchrest, Romni, between April nd July 1990 on systemtic
More informationEstimating the impact of the 2009 influenza A(H1N1) pandemic on mortality in the elderly in Navarre, Spain
Rpid communictions Estimting the impct of the influenz pndemic on mortlity in the elderly in Nvrre, Spin J Cstill (jcstilc@nvrr.es) 1, J Etxeberri 1, E Ardnz 1, Y Floristán 1, R López Escudero 1, M Guevr
More informationOne of the most important biological mechanisms of
Brief Report Serum Thymidine Kinse 1 Activity in the Prognosis nd Monitoring of Chemotherpy in Lung Cncer Ptients: A Brief Report Benjmin Nismn, PhD,* Hovv Nechushtn, MD, PhD,* Him Birn, MD, Hds Gntz-Sorotsky,
More informationOriginal Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:
Fridpur Med. Coll. J. 214;9(2):61-67 Originl Article Nebuliztion by Isotonic Mgnesium Sulphte Solution with Provide Erly nd Better Response s Compred to Conventionl Approch ( Plus Norml Sline) in Acute
More informationAddendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)
Addendum to the Evidence Review Group Report on Aripiprzole for the tretment of schizophreni in dolescents (ged 15-17 yers) Produced by Authors Correspondence to Southmpton Helth Technology Assessments
More informationR Martino 1, P Romero 1, M Subirá 1, M Bellido 1, A Altés 1, A Sureda 1, S Brunet 1, I Badell 2, J Cubells 2 and J Sierra 1
Bone Mrrow Trnsplnttion, (1999) 24, 283 287 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Comprison of the clssic Glucksberg criteri nd the IBMTR Severity
More informationA cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis
Originl Article A cross-sectionl nd follow-up study of leukopeni in tuberculosis ptients: prevlence, risk fctors nd impct of nti-tuberculosis tretment Fei-Shen Lin 1 *, Mei-Ying Wu 2 *, Wen-Jun Tu 3, Hong-Qiu
More informationULTOMIRIS is administered once every 8 weeks a
(rvulizumb-cwvz) for the tretment of dult ptients with proxysml nocturnl hemoglobinuri (PNH) is dministered once every 8 weeks PATIENTS STARTING WITH NO PRIOR TREATMENT FOR PNH THE RECOMMENDED DOSING REGIMEN
More informationRecall Bias in Childhood Atopic Diseases Among Adults in The Odense Adolescence Cohort Study
Syddnsk Universitet Recll Bis in Childhood Atopic Diseses Among Adults in The Odense Adolescence Cohort Study Mørtz, Chrlotte G; Andersen, Klus Ejner; Bindslev-Jensen, Crsten Published in: Act Dermto-Venereologic
More informationTHE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS
THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS John F. Ptience nd Doug Gillis SUMMARY
More informationEFFECTS OF AN ACUTE ENTERIC DISEASE CHALLENGE ON IGF-1 AND IGFBP-3 GENE EXPRESSION IN PORCINE SKELETAL MUSCLE
Swine Dy 22 Contents EFFECTS OF AN ACUTE ENTERIC DISEASE CHALLENGE ON IGF-1 AND IGFBP-3 GENE EXPRESSION IN PORCINE SKELETAL MUSCLE B. J. Johnson, J. P. Kyser, J. D. Dunn, A. T. Wyln, S. S. Dritz 1, J.
More informationAntiviral Therapy 2015; 20: (doi: /IMP2874)
Antivirl Therpy 25; 2:79 79 (doi:.385/imp2874) Originl rticle Single dose permivir for the tretment of cute sesonl influenz: integrted nlysis of efficcy nd sfety from two plcebo-controlled trils Richrd
More informationmsmr MEDICAL SURVEILLANCE MONTHLY REPORT INSIDE THIS ISSUE: A publication of the Armed Forces Health Surveillance Center Summary tables and figures
VOL. 17 NO. 09 SEPTEMBER 2010 msmr A publiction of the Armed Forces Helth Surveillnce Center MEDICAL SURVEILLANCE MONTHLY REPORT Source: CDC INSIDE THIS ISSUE: Contct trnsfer of vccini virus from U.S.
More informationMortality of patients with multiple sclerosis: a cohort study in UK primary care
Mortlity of ptients with multiple sclerosis: cohort study in UK primry cre The Hrvrd community hs mde this rticle openly vilble. Plese shre how this ccess benefits you. Your story mtters Cittion Jick,
More informationAnemia in pediatric hemodialysis patients: Results from the 2001 ESRD Clinical Performance Measures Project
Kidney Interntionl, Vol. 64 (2003), pp. 1120 1124 Anemi in peditric hemodilysis ptients: Results from the 2001 ESRD Clinicl Performnce Mesures Project DIANE L. FRANKENFIELD, ALICA M. NEU, BRADLEY A. WARADY,
More informationDose-dependent effect of daptomycin on the artificial prolongation of prothrombin time in coagulation abnormalities: in vitro verification
Hshimoto et l. BMC Phrmcology nd Toxicology (2017) 18:74 DOI 10.1186/s40360-017-0180-3 RESEARCH ARTICLE Open Access Dose-dependent effect of dptomycin on the rtificil prolongtion of prothrombin time in
More informationDid introduction of pneumococcal vaccines in the Netherlands decrease the need for respiratory antibiotics in children? Analysis of 2002 to 2013 data
Reserch rticles Did introduction of pneumococcl vccines in the Netherlnds decrese the need for respirtory ntibiotics in children? Anlysis of 2002 to 2013 dt G Gefenite (g.gefenite@lumnus.rug.nl) 1,2, M
More informationStaffing Model for Dental Wellness and Readiness
MILITARY MEDICINE, 169, 8:604, 2004 Stffing Model for Dentl Wellness nd Rediness Gurntor: LTC Jeffrey Chffin, DC USA Contributors: COL Lrry G. Rothfuss, DC USA* ; LCDR Scott A. Johnson, NC USN* ; MAJ Stephen
More informationInfluenza A and Inactivated Trivalent Influenza Virus Vaccines in Older Adults with Chronic Diseases
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1986, p. 336-342 0095-1137/86/090336-07$02.00/0 Copyright 1986, Americn Society for Microbiology Vol. 24, No. 3 Sfety of nd Serum Antibody Response to Cold-Recombinnt
More informationAnalysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia
284 Anlysis of lterntives for izing ptients to chieve glycemic control nd void ccompnying risks of hypoglycemi JIALIN GAO 1,2*, QIANYIN XIONG 1,2*, JUN MIAO 1*, YAO ZHANG 2,3, LIBING XIA 1, MEIQIN LU 1,
More informationENERGY CONTENT OF BARLEY
ENERGY CONTENT OF BARLEY VARIATION IN THE DIETARY ENERGY CONTENT OF BARLEY Shwn Firbirn, John Ptience, Hnk Clssen nd Ruurd Zijlstr SUMMARY Formultion of commercil pig diets requires n incresing degree
More informationMetformin and breast cancer stage at diagnosis: a population-based study
ORIGINAL ARTICLE METFORMIN AND BREAST CANCER STAGE AT DIAGNOSIS, Leg et l. Metformin nd brest cncer stge t dignosis: popultion-bsed study I.C. Leg md msc,* K. Fung msc,* P.C. Austin phd, nd L.L. Lipscombe
More informationThe Quality and Outcomes Framework (QOF) is a pay-for-performance
Effect of UK Py-for-Performnce Progrm on Ethnic Disprities in Dibetes Outcomes: Interrupted Time Series Anlysis Riydh Alshmsn, MSc John Tyu Lee, MSc Azeem Mjeed, MD Goplkrishnn Netuveli, PhD Christopher
More informationUniversity of Texas Health Science Center, San Antonio, San Antonio, Texas, USA
Lung Cncer Chemotherpy Given Ner the End of Life by Community Oncologists for Advnced Non-Smll Cell Lung Cncer Jose R. Murillo, Jr., Jim Koeller b,c Methodist Hospitl, Houston, Texs, USA; b University
More informationEvaluation of the TEST 1 erythrocyte sedimentation rate system and intra- and inter-laboratory quality control using new latex control materials
Clin Chem Lb Med 2010;48(7):1043 1048 2010 by Wlter de Gruyter Berlin New York. DOI 10.1515/CCLM.2010.162 Evlution of the TEST 1 erythrocyte sedimenttion rte system nd intr- nd inter-lbortory qulity control
More informationInadequate health literacy is a
Testing the BRIEF Helth Litercy Screening Tool Jolie Hun, PhD, Virgini Nolnd-Dodd, PhD, MPH, Jill Vrnes, EdD, John Grhm-Pole, MD, Brbr Rienzo, PhD, nd Ptrici Donldson, RN Due to the oppressive strins lid
More informationAnalysis of Regulatory of Interrelated Activity of Hepatocyte and Hepatitis B Viruses
Interntionl Journl of Biomedicl Mterils Reserch 8 6(): -7 http://www.sciencepublishinggroup.com/j/ijbmr doi:.648/j.ijbmr.86. ISSN: 33-756 (Print) ISSN: 33-7579 (Online) Anlysis of Regultory of Interrelted
More informationLipase and Pancreatic Amylase Activities in Tissues and in Patients with Hyperamylasemia
CLINICAL CHEMISTRY Originl Article Lipse nd Pncretic Amylse Activities in Tissues nd in Ptients with Hypermylsemi FRED APPLE, PH.D, PETER BENSON, M.D., LYNNE PREESE, MT, M.B.A., STEVEN EASTEP, M.D., LAURA
More informationOriginal Article INTRODUCTION. Korean Diabetes J 2010;34: doi: /kdj pissn eissn
Originl Article doi: 1.493/kdj.21.34.6.34 pissn 1976-918 eissn 293-265 The Smll Rice Bowl-Bsed Mel Pln ws Effective t Reducing Dietry Energy Intke, Body Weight, nd Blood Glucose Levels in Koren Women with
More informationThe Effects of Small Sized Rice Bowl on Carbohydrate Intake and Dietary Patterns in Women with Type 2 Diabetes
Originl Article doi: 10.4093/kdj.2010.34.3.166 pissn 1976-9180 eissn 2093-2650 The Effects of Smll Sized Rice Bowl on Crbohydrte Intke nd Dietry Ptterns in Women with Type 2 Dibetes Hee-Jung Ahn 1, *,
More informationImpact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting
Impct of Phrmcist Intervention on Dibetes Ptients in n Ambultory Setting Julie Stding, PhrmD, CDE, Jmie Herrmnn, PhrmD, Ryn Wlters, MS, Chris Destche, PhrmD, nd Aln Chock, PhrmD Dibetes is the seventh-leding
More informationMETHOD 4010 SCREENING FOR PENTACHLOROPHENOL BY IMMUNOASSAY
METHOD 4010 SCREENING FOR PENTACHLOROPHENOL BY IMMUNOASSAY 1.0 SCOPE AND APPLICATION 1.1 Method 4010 is procedure for screening solids such s soils, sludges, nd queous medi such s wste wter nd lechtes
More informationNonpharmacologic Interventions for Treatment-Resistant Depression in Adults Executive Summary
Comprtive Effectiveness Review Numer 33 Effective Helth Cre Progrm Nonphrmcologic Interventions for Tretment-Resistnt Depression in Adults Executive Summry Bckground Mjor depressive disorder (MDD) is common
More informationAntibody Response to a Human Diploid Cell Rabies Vaccine
APPLIE MIROBIOLOGY, Mr. 1974, P. 553-561 opyright 1974 Americn Society for Microbiology Vol. 27, No. 3 Printed in U.S.A. Antibody Response to Humn iploid ell Rbies Vccine V. J. ABASSO, M. B. OBKIN, R.
More informationTreatment of leukemia with partially matched related bone marrow transplantation
Bone Mrrow Trnsplnttion, (1997) 19, 421 427 1997 Stockton Press All rights reserved 268 3369/97 $12. Tretment of leukemi with prtilly mtched relted bone mrrow trnsplnttion RK Munn 1, PJ Henslee-Downey
More informationBODY OF REPORT. SEAT0 Medic Study No. 4. Serologic Response to Tha.i Hemorrha.gic Fever Virus Infection. Project No.
BODY OF REPORT SEAT Medic Study No. 4 Project No. 3A 2561 A 811 Tsk 1: Serologic Response to Th.i Hemorrh.gic Fever Virus Infection Mi1it.q Medicl Reserch Prgr.m S. E. Asi. Mi1it.r~ Medic.1 Rese.rch Prgr.m
More informationOptimisation of diets for Atlantic cod (Gadus morhua) broodstock: effect of arachidonic acid on egg & larval quality
Optimistion of diets for Atlntic cod (Gdus morhu) roodstock: effect of rchidonic cid on egg & lrvl qulity Dr Gordon Bell, Ms. An Blnco, Dr Bill Roy, Dr Derek Roertson, Dr Jim Henderson nd Mr Richrd Prickett,
More informationin the above manner contained 105 to 106 plaqueforming virus preparation was used without further manipulation
INFECTION AND IMMUNITY, June 1978, p. 660-664 0019-9567/78/0020-tE60$02.00/0 Copyright 1978 Americn Society for Microbiology Vol. 20, No. 3 Printed in U.S.A. Enzyme-Linked Immunosorbent Assy for Mesurement
More informationadministration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies
Lessons from Cub: mss cmpign dministrtion of trivlent orl poliovirus vccine nd seroprevlence of poliovirus neutrlizing ntibodies P. Ms Lgo,1 J. Rmon Brvo,1 J.K. Andrus,2 M.M. Comells,1 M.A. Glindo,3 C.A.
More informationWSU Tree Fruit Research and Extension Center, Wenatchee (509) ext. 265;
FINAL REPORT WTFRC Project # AH-1-5 WSU Project # 13C-355-3 Project title: PI: Orgniztion: Coopertors: of Sunburn in Apples with RAYNOX Lrry Schrder, Horticulturist WSU Tree Fruit Reserch nd Extension
More informationUsing Paclobutrazol to Suppress Inflorescence Height of Potted Phalaenopsis Orchids
Using Pcloutrzol to Suppress Inflorescence Height of Potted Phlenopsis Orchids A REPORT SUBMITTED TO FINE AMERICAS Linsey Newton nd Erik Runkle Deprtment of Horticulture Spring 28 Using Pcloutrzol to Suppress
More informationRisks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria
Clinicl Prctice: Mini-Review Received: My 20, 2016 Accepted fter revision: December 14, 2016 Published online: Jnury 27, 2017 Risks for All-Cuse Mortlity: Strtified by Age, Estimted Glomerulr Filtrtion
More informationAppendix J Environmental Justice Populations
Appendix J Environmentl Justice s [This pge intentionlly left blnk] Tble of Contents REFERENCES...J-2 Pge LIST OF TABLES Pge Tble J-1: Demogrphic Overview of Bruinsburg Site Project Are... J-3 Tble J-2:
More informationLATE RESULTS OF TRANSFER OF THE TIBIAL TUBERCLE FOR RECURRENT DISLOCATION OF THE PATELLA1
LATE RESULTS OF TRANSFER OF THE TIBIAL TUBERCLE FOR RECURRENT DISLOCATION OF THE PATELLA1 W. G. J. HAMPSON nd P. HILL, BRISTOL, ENGLAND The uthors wished to determine the lte results of the Huser opertion,
More informationA Two-Stage Sampling Method for Clinical Surveillance of Individuals in Care for HIV Infection in the United States
Reserch Articles A Two-Stge Smpling Method for Clinicl Surveillnce of Individuls in Cre for HIV Infection in the United Sttes Ptrick S. Sullivn, DVM, PhD John M. Kron, PhD Fye E. Mlitz, MPH b Stephnie
More informationWeight-Based Dosage Regimen: (2.1) Body Weight Range (kg) Loading Dose (mg) Maintenance Dose (mg) greater or equal to 40 to less than 60 2,400 3,000
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (rvulizumb-cwvz) injection, for intrvenous
More informationMuhammad Shoaib, Muhammad Usman, Rabia Fatima, Sajid Aziz, Muhammad Wasif Malik, Muhammad Javaid Asad and Sikandar Khan Sherwani
Americn-Eursin Journl of Toxicologicl Sciences 7 (4): 214-219, 2015 ISSN 2079-2050 IDOSI Publictions, 2015 DOI: 10.5829/idosi.ejts.2015.7.4.9447 Reltionship Among Alnine Amino-Trnsferse (ALT), Prtil Thromboplstin
More informationClinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer
Clinicl Evidence for Second- nd Third-Line Tretment Options in Advnced Non-Smll Cell Lung Cncer Filippo de Mrinis, Frncesco Grossi b Thorcic Oncology Unit I, Deprtment of Lung Diseses, Sn Cmillo nd Forlnini
More informationY. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3
Greter remission rtes in ptients with erly versus long-stnding disese in biologic-nive rheumtoid rthritis ptients treted with btcept: post hoc nlysis of rndomised clinicl tril dt Y. Yzici 1, D. Moniz Reed
More informationUsing proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience
ORIGINAL ARTICLE Using prolifertive mrkers nd Oncotype DX in therpeutic decision-mking for brest cncer: the B.C. experience E. Bxter bsc,* L. Gondr btech pdc, C. Lohrisch md, S. Chi md, K. Gelmon md, M.
More informationcapacity in infants and children
Archives of Disese in Childhood, 1974, 49, 654. DDAVP test for estimtion of renl concentrting cpcity in infnts nd children A. S. ARONSON nd N. W. SVENNINGSEN From the Deprtment of Peditrics, University
More informationURINARY incontinence is an important and common
Urinry incontinence in older people in the community: neglected problem? Helen Stoddrt, Jenny Donovn, Elise Whitley, Deborh Shrp nd In Hrvey SUMMARY Bckground: The prevlence nd impct of urinry incontinence
More informationMetabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction
Metbolic Syndrome nd Helth-relted Qulity of Life in Obese Individuls Seeking Weight Reduction Adm Gilden Tsi 1, Thoms A. Wdden 1, Dvid B. Srwer 1, Robert I. Berkowitz 1, Leslie G. Womble 1, Louise A. Hesson
More informationDiabetes affects 29 million Americans, imposing a substantial
CLINICAL Comprtive Effectiveness nd Costs of Insulin Pump Therpy for Dibetes Ronld T. Ackermnn, MD, MPH; Amish Wlli, MD, MS; Rymond Kng, MA; Andrew Cooper, MPH; Theodore A. Prospect, FSA, MAAA; Lewis G.
More informationHuman leukocyte antigen-drb1 polymorphism in childhood acute lymphoblastic leukemia
MOLECULAR AND CLINICAL ONCOLOGY 3: 425-429, 2015 Humn leukocyte ntigen-drb1 polymorphism in childhood cute lymphoblstic leukemi MERVAT M. EL ANSARY 1, LAMIAA A. MOHAMMED 2, TAMER H. HASSAN 3, AHMED BARAKA
More informationPrognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic
Crcinogenesis, 2015, Vol. 36, No. 2, 243 248 doi:10.1093/crcin/bgu247 Advnce Access publiction December 18, 2014 Originl Mnuscript originl mnuscript Prognostic significnce of pretretment serum levels of
More informationBody mass index, waist-to-hip ratio, and metabolic syndrome as predictors of middle-aged men's health
Originl Article - Sexul Dysfunction/Infertility pissn 2005-6737 eissn 2005-6745 Body mss index, wist-to-hip rtio, nd metbolic syndrome s predictors of middle-ged men's helth Jung Hyun Prk *, In-Chng Cho
More informationTHE CHB TREATMENT GUIDELINE NAVIGATOR REVIEW AN ONLINE INTERACTIVE GUIDE FOR CLINICIANS FEATURING EXPERT AUDIO COMMENTARY
The Americn Assocition for the Study of Liver Diseses () nd the Europen Assocition for the Study of Liver Disese () provide clinicl prctice guidelines for the mngement nd tretment of chronic heptitis B
More informationThe Acute Time Course of Concurrent Activation Potentiation
Mrquette University e-publictions@mrquette Exercise Science Fculty Reserch nd Publictions Exercise Science, Deprtment of 1-1-2010 The Acute Time Course of Concurrent Activtion Potentition Luke Grceu Mrquette
More informationDR. MARC PAGÈS Project Manager R&D Biologicals - Coccidia Projects, HIPRA
DR. MARC PAGÈS Project Mnger R&D Biologicls - Coccidi Projects, HIPRA Dr. Mrc Pgès Bosch otined Microiology nd Genetics degree t the University of Brcelon in 1998. He otined his PhD working on the synptoneml
More informationComparison of Bovine Herpesvirus 1 Vaccines for Rapid Induction of Immunity*
Comprison of Bovine Herpesvirus 1 Vccines for Rpid Induction of Immunity Jmes A. Roth, DVM, PhD,b Dvid P. Crter, DVM b Deprtment of Veterinry Microbiology nd Preventive Medicine College of Veterinry Medicine
More information